Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Medicare drug plans can now cover Eli Lilly's blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare & Medicaid Services confirmed to CNBC. That opens the door for ...

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly ...

A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.